Nutrispectives, Spokane, WA, United States.
Adv Nutr. 2023 Jul;14(4):585-591. doi: 10.1016/j.advnut.2023.04.008. Epub 2023 Apr 25.
Current regulations require that the assessment of protein quality in infant formula be determined using the protein efficiency ratio (PER) rat bioassay where the growth of rats fed a test protein is compared with the growth of rats fed casein. This review cites authoritative body opinions that the PER is not a preferred method for scoring protein quality, particularly as applied to the infant formula. Methodological recommendations specified by FDA and recent guidance propose to control nonprotein dietary variables in the PER. In contrast, the essential amino acid pattern of human milk has been adopted internationally as the standard for protein quality in infant formula. Because casein, the control protein in the PER fails to meet the standard of human milk essential amino acids, the PER based on casein can generate a false assurance of the quality of protein in an infant formula. FDA should revise the method of demonstrating the quality factor for the biological quality of protein to the essential amino acid pattern of human milk, which would be simpler, conform to international standards, and should be considered by FDA under a new statute. Alternate methods of determination of protein quality can be used selectively when there are questions about the digestibility of new protein sources or the effects of manufacturing processes.
现行法规要求,婴儿配方食品中蛋白质质量的评估必须使用蛋白质效率比(PER)大鼠生物测定法来确定,该方法通过比较喂食测试蛋白质的大鼠的生长情况与喂食酪蛋白的大鼠的生长情况来进行。本文引用了权威机构的意见,即 PER 不是一种首选的蛋白质质量评分方法,特别是在婴儿配方食品方面。FDA 规定的方法建议和最近的指导方针建议在 PER 中控制非蛋白质饮食变量。相比之下,母乳的必需氨基酸模式已被国际上采用为婴儿配方食品中蛋白质质量的标准。由于 PER 中使用的对照蛋白质酪蛋白不符合母乳必需氨基酸的标准,因此基于酪蛋白的 PER 可能会对婴儿配方食品中蛋白质的质量产生错误保证。FDA 应将证明蛋白质生物质量质量因素的方法修订为与母乳必需氨基酸模式一致,这将更加简单,符合国际标准,并且应在新法规下由 FDA 进行考虑。当涉及到新蛋白质来源的消化率或制造过程的影响等问题时,可以选择性地使用其他蛋白质质量测定方法。